Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination

PURPOSE: NSABP B-41, a phase three randomized trial, evaluated neoadjuvant lapatinib, trastuzumab, or the combination with chemotherapy in patients with HER2-positive operable breast cancer. Though no significant difference in pathologic complete response (pCR) was found among the three arms, pCR wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Swain, Sandra M., Tang, Gong, Lucas, Peter C., Robidoux, André, Goerlitz, David, Harris, Brent T., Bandos, Hanna, Geyer, Charles E., Rastogi, Priya, Mamounas, Eleftherios P., Wolmark, Norman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797698/
https://www.ncbi.nlm.nih.gov/pubmed/31428908
http://dx.doi.org/10.1007/s10549-019-05398-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797698/
https://www.ncbi.nlm.nih.gov/pubmed/31428908
http://dx.doi.org/10.1007/s10549-019-05398-3

Ejemplares similares